

To: (10)(2e) [(10)(2e)@rivm.nl]
From: ACIV Chair
Sent: Thur 9/3/2020 4:11:32 PM
Subject: SARS CoV-2 vaccine update
Received: Thur 9/3/2020 4:11:36 PM

In collaboration with North Dakota State University, this week we released a comprehensive review of COVID-19 vaccine development.

COVID-19 vaccine development has been progressing rapidly and clinical trials are underway for 8 different drugs. Camostat mesylate is one of the most promising and Yale University is starting a phase II clinical trial to test if oral Camostat mesylate can reduce virus transmission and complications.

This research will also be featured in the COVID-19 session of the 2021 Annual Conference on Immunology and Virology.

If you would like a PDF of the review or more information about participation in the conference please let me know or explore the links in my signature below.

Would you be willing to discuss joining the conference as a speaker or delegate?

Sincerely,

(10)(2e)

[Annual Conference on Immunology and Virology](#)
[View Scientific Program](#)

This communications and any attachments is not to be read or shared by anyone other than the named recipient. Information within this message may be protected by copyright. This message is intended to be a B2B communication. If you are not the named recipient please remove this message from your computer. Do not open any unknown attachments as they could harm your computer. If you have received this email in error or wish to remove your data from our system please reply, or contact us at 340 S. Lemon Ave, Walnut CA 91789.

Please do not print this email unless it is necessary. Every unprinted email helps the environment. sender does not accept liability for any damage inflicted by viewing the content of this email.